Gsk Share Discussion Threads

[essentialinvestor] 07/12/2016 10:14

Far from it of late, but taking nothing away from his exceptional longer term
record.

[ianood] 07/12/2016 10:11

EI - agree just goes to show Mr Woodford is not invincible

[essentialinvestor] 07/12/2016 09:29

The ViiV CEO leaving next April, may suggest no quick spin off
and the correct decision in my view.

If GSK had caved to pressure for a separate listing 12 months ago the loss
on potential value to the Company would be significant with
huge rates of growth seen since, even if GSK had retained a % stake.

[dr biotech] 07/12/2016 08:10

Ok let's move on.

Pfizer has been fined £84m for gouging the NHS this morning. How many times have they crossed the line? Drug pricing and the cost of developing them has to be addressed but no-one wants to take it on

[mj19] 06/12/2016 22:20

All on the 6th Dec

[mj19] 06/12/2016 22:08

GlaxoSmithKline plc (GSK) Receives Buy Rating from Beaufort SecuritiesPosted by Jared Coughlin on Dec 6th, 2016 // No CommentsGlaxoSmithKline plc logoBeaufort Securities reaffirmed their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report report published on Monday.Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank AG set a GBX 1,760 ($22.36) price target on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research report on Wednesday, November 30th. HSBC reissued a buy rating and set a GBX 1,970 ($25.03) price target on shares of GlaxoSmithKline plc in a research report on Monday, September 12th. Berenberg Bank set a GBX 1,885 ($23.95) price target on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research report on Tuesday, August 9th. Sanford C. Bernstein set a GBX 1,834 ($23.30) price target on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research report on Wednesday, October 19th. Finally, Shore Capital reissued a hold rating on shares of GlaxoSmithKline plc in a research report on Wednesday, August 17th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of GBX 1,729.78 ($21.98).

[mj19] 06/12/2016 22:07

December 6th, 2016 - By Renee Jackson - 0 commentsGlaxoSmithKline plc logoGoldman Sachs Group Inc. reissued their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report released on Thursday morning.Several other analysts have also commented on the company. JPMorgan Chase & Co. cut their price objective on GlaxoSmithKline plc from GBX 1,900 ($24.14) to GBX 1,800 ($22.87) and set a neutral rating for the company in a report on Tuesday, November 1st. Deutsche Bank AG set a GBX 1,760 ($22.36) price objective on GlaxoSmithKline plc and gave the stock a neutral rating in a report on Wednesday, November 30th. Bryan, Garnier & Co reaffirmed a buy rating on shares of GlaxoSmithKline plc in a report on Monday, October 17th. Citigroup Inc. reaffirmed a buy rating on shares of GlaxoSmithKline plc in a report on Monday, November 7th. Finally, Beaufort Securities reaffirmed a buy rating on shares of GlaxoSmithKline plc in a report on Tuesday, September 6th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and nine have assigned a buy rating to the company's stock. The stock presently has a consensus rating of Hold and an average target price of GBX 1,729.78 ($21.98).

[mj19] 06/12/2016 22:06

GlaxoSmithKline plc 23.5% Potential Upside Indicated by JP Morgan CazenovePosted by: Amilia Stone 6th December 2016GlaxoSmithKline plc using EPIC/TICKER code LON:GSK has had its stock rating noted as 'Retains' with the recommendation being set at 'NEUTRAL' this morning by analysts at JP Morgan Cazenove. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set a target price of 1800 GBX on its stock. This is indicating the analyst believes there is a potential upside of 23.5% from today's opening price of 1457.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 91.5 points and decreased 168 points respectively.

[essentialinvestor] 06/12/2016 16:44

Good to hear M.

Having some cash to deploy is usually wise, timing is the more difficult bit.

Would not discount a dip below £14, however on a risk/return basis
around the current share price already looks interesting, just my take.

[minerve] 06/12/2016 16:37

Don't worry Essential - not your fault.

Look, let's forget about PREP. I apologize to Dr Biotech for being offensive. I do tend to get quite passionate about these things particularly when they are important issues that affect us all and especially when it affects our children and younger generations.

[essentialinvestor] 06/12/2016 16:19

I'm sorry I mentioned Prep!, appreciate people have very different views on
the subject, it was only re GSK and ViiV that thought it was worth posting.


Hoped for 14.45 or lower today but did not quite get there, unless I missed it.

[atlantic57] 06/12/2016 16:01

Cash is the riskiest of all assets at the moment

[garycook] 06/12/2016 13:00

Stay in cash then !!!

[dr biotech] 06/12/2016 12:04

Might be a long wait. I'm not really sure of a good place to invest right now, everything looks a bit risky.

[tradermichael] 06/12/2016 11:48

Yes, but happy to be heavily invested - the dividends are very healthy while a stream of new products emerges .....

[dr biotech] 06/12/2016 11:31

We have lost the share price gain that we had from the plunge in the exchange rate - was about 1.45 at the time of brexit giving us a 20% boost in earnings. I think it has dropped too far, but I am still sitting on the sidelines.

Are you still very long TM? That must be hurting right now. :-( Have my sympathies if you are, I have had a mixed year.

[tradermichael] 06/12/2016 11:18

Well, only if the pound is stronger against the dollar

[montyhedge] 06/12/2016 11:12

Strong pound, makes Astra and GSK shareprice weaker.

[bracke] 06/12/2016 11:06

Maybe support at the dashed pink line but 13.62 more probable.

GSK DAILY

[philanderer] 06/12/2016 09:55

6th dec JP Morgan neutral tp 1800p

reiteration

[minerve] 06/12/2016 09:54

"Either way his kids teenage years are going to be hard."

But not as hard as losing a younger brother or sister to a rare form of cancer that the NHS don't want to fork out for because they want to spend it on silly populist/PC ideas like PREP, eh?

[dr biotech] 06/12/2016 09:49

Sometimes if you get it early then the progression is quicker, but that tends to apply more to the 20s. He only found out when they gave him a brain scan. He thought it was some stress related issues - obviously a bit of a shock. I think most are only diagnosed late on, he was at a very early stage.

[essentialinvestor] 06/12/2016 09:12

38?, that is atypical so may be following a different disease progression.

[dr biotech] 06/12/2016 09:07

Friend of mine was diagnosed at 38. His son is my sons best friend - that was 6 years ago. He has been taking some new therapy and is doing ok. Even now you wouldn't really know - perhaps it's the therapy or more likely the progress is fortunately slow in him. Either way his kids teenage years are going to be hard.

[essentialinvestor] 06/12/2016 08:40

The lack of progress on dementia/AD research is incredibly depressing.

We look a decade away from anything effective.